Novo Nordisk Pays Up to €1.165 Billion for Nanexa Drug-Delivery License

The deal and the technology

Novo Nordisk secured exclusive global rights to use Nanexa's Atomic Layer Deposition drug delivery platform for obesity and diabetes, per Nanexa. Novo will take the lead on worldwide development and commercialization of any resulting products.

Nanexa's system is built to release drugs in a controlled way over time by forming a depot in the body. That steady release could stretch dosing intervals to monthly or even quarterly injections. Financially, the package includes a €615 million upfront payment, potential development and regulatory milestones across as many as five development programs, and royalties in the low single digits based on global net sales.

Market reaction and context

Investors piled in. Nanexa's stock climbed up to 161% in Stockholm, its biggest single-day surge since the company listed in 2015. Based on Thursday's close, the agreement could be worth over 10 times Nanexa's market value. Novo's shares showed minimal movement in Copenhagen.

The announcement comes just days after Novo frustrated investors by offering few specifics on how it plans to return to growth after ceding its lead in the obesity boom to Eli Lilly & Co. According to Novo Chief Executive Officer Mike Doustdar, the strategy still includes acquisitions - primarily smaller bolt-ons - though he emphasized the company also has capacity for significantly larger deals.

Major business moves highlight why steady planning helps protect and grow your savings. Join Briefs Finance CEO Jaspreet Singh on September 29th for a FREE live investor workshop, How to Profit From A Dollar That's Losing its Value, where he shows how we're spotting investment opportunities as the dollar falls. Save your spot.

Pipeline push and how near this is to patients

This is Novo's third agreement in a little over a week as it works to shore up its pipeline ahead of early next decade patent expirations for Ozempic and Wegovy. Together, the trio of actions includes partnering with Denmark's Orbis Medicines ApS in a deal valued at $1.4 billion, acquiring three prospective obesity candidates from New York's Kallyope Inc., and securing the Nanexa license. All three are relatively small stakes in efforts that are far from reaching patients.

"Novo is getting access to a technology it has long wanted," wrote Per Hansen, investment economist at Nordnet, in a note to clients. Even so, he said the move is "unlikely to be a short-term share price trigger." He added, "It's certain that it will be a very good day for Nanexa's shareholders."

Background ties and takeaways

The companies are not strangers. They inked a 2022 agreement around Nanexa's PharmaShell delivery system, and Nanexa's chairman, Goran Ando, served as a Novo board member during 2005-2018, including five years as chairman.

For your wallet, the through-line is simple: pharma giants often place targeted bets on platforms that can stretch dosing and improve adherence. The payoff timeline can be long, but when a technology solves a delivery problem, markets notice quickly, even if the products are years away.

Complex deals underscore the value of calm strategies that preserve capital and opportunity. Our CEO Jaspreet Singh is hosting a FREE live investor workshop, How to Profit From A Dollar That's Losing its Value, on September 29th. Sign up free to join him live.